Core Insights - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with significant milestones expected in 2026, including pivotal data for vonaprument and tanruprubart [1][2][3] Company Developments - Vonaprument is positioned to be the first vision-preserving therapy for geographic atrophy (GA), a major cause of blindness affecting over 8 million patients globally [3][4] - The Phase 3 ARCHER II trial for vonaprument has completed enrollment with 659 patients, focusing on visual acuity as the primary endpoint [3][7] - Tanruprubart has been filed for Marketing Authorization Application (MAA) in Europe, aiming to be the first targeted fast-acting therapy for Guillain-Barré Syndrome (GBS), impacting approximately 150,000 people annually [4][6] - ANX1502 is advancing as the first oral C1 inhibitor for autoimmune diseases, with proof-of-concept data anticipated in 2026 [5][6] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling approximately $238.3 million, providing a runway into the second half of 2027 [1][7] - Research and development (R&D) expenses for Q4 2025 were $42.7 million, with a total of $184.7 million for the year, reflecting increased investment in late-stage programs [7][8] - General and administrative (G&A) expenses were $7.6 million for Q4 2025, showing a decrease from the previous year, indicating improved corporate efficiencies [7][8] Strategic Focus - The company is leveraging its scientific platform to develop therapies that target neuroinflammation at its source, with a focus on the C1q pathway [2][8] - The ongoing FORWARD study in the U.S. and Europe aims to broaden the experience with tanruprubart and support a planned Biologics License Application (BLA) submission in 2026 [3][7] - The company hosted an Investor Day in March 2026, showcasing the differentiated mechanism of action of vonaprument and its clinical development strategy [3]

Core Viewpoint - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with a focus on dry age-related macular degeneration (AMD) and geographic atrophy (GA), impacting nearly 10 million people globally [1][8] Company Overview - Annexon is a biopharmaceutical company specializing in immunotherapies aimed at neuroinflammatory diseases [1][8] - The company is developing vonaprument, a C1q inhibitor designed to be the first targeted vision-preserving therapy for GA [6][8] Event Announcement - Annexon will host a key opinion leader (KOL) event in New York on March 18, 2026, featuring presentations on dry AMD and GA [1][2] - The event will include a live Q&A session following the formal presentations [2] Expert Contributions - Dr. Eleonora Lad and Dr. Charles C. Wykoff will present at the event, focusing on the unmet needs in GA treatment and the mechanism of disease [5] - Dr. Lad's research includes the role of neuroinflammation in AMD and the development of innovative diagnostic approaches [3] - Dr. Wykoff has extensive experience in clinical trials and research related to retinal diseases [4] Product Development - Vonaprument is a clinical-stage investigational therapy that selectively inhibits C1q, aiming to protect retinal function [6] - The drug has received Fast Track designation from the FDA and Priority Medicine designation from the European Medicines Agency [6] Clinical Trial Information - The Phase 3 ARCHER II trial has enrolled over 630 patients with advanced dry AMD and GA, with a primary endpoint of preventing a ≥15-letter loss in best corrected visual acuity [7] - Topline data from the trial is expected in the second half of 2026 [7]

Core Insights - Annexon, Inc. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart, a potential first targeted fast-acting therapy for Guillain-Barré syndrome (GBS) [1][2] - The company plans to submit a Biologics License Application (BLA) to the FDA in 2026, with data from the ongoing FORWARD trial [1][3] Company Overview - Annexon is focused on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally [1][7] - The company aims to provide meaningful functional benefits and alter the course of diseases by stopping classical complement-driven neuroinflammation [7] Product Details - Tanruprubart is a first-in-class antibody designed to block classical complement-driven inflammation, showing rapid effects in stopping early nerve damage in GBS patients [2][4] - The therapy has received Orphan Drug designations from both the FDA and EMA, indicating a recognized need for improved treatments [2][5] Clinical Data - The MAA submission included comprehensive data demonstrating that tanruprubart allows patients to recover faster and more completely compared to existing treatments [3][4] - The ongoing FORWARD study aims to support a broad label for both pediatric and adult patients, expanding the use of tanruprubart across different geographies [3][4] Disease Context - GBS is a rare neuromuscular emergency affecting over 150,000 people annually worldwide, with no approved treatments in the U.S. [2][6] - The disease leads to significant morbidity and has a multi-billion-dollar annual economic cost to the U.S. healthcare system [6]

Core Viewpoint - MAIA Biotechnology, Inc. has announced a private placement of 603,769 shares of common stock at a price of $1.22 per share, along with warrants for additional shares, aimed at raising approximately $736,600 to fund clinical trials and working capital [1][2]. Group 1: Private Placement Details - The private placement involves the sale of 603,769 shares at $1.22 each, with each share accompanied by a warrant to purchase one additional share at an exercise price of $1.52 [1]. - The warrants will be exercisable six months after issuance and will have a term of three years [1]. - The expected gross proceeds from the offering are approximately $736,600, before expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital [2]. Group 3: Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5].

Core Viewpoint - Calidi Biotherapeutics is undergoing significant transformation in leadership, focus, and financial management, aiming to advance its innovative oncology therapies, particularly the RedTail platform, which shows promise in delivering genetic medicines to metastatic cancer sites [1][3][7]. Company Developments - The appointment of Eric Poma as CEO in April 2025 marks a new leadership direction, with a focus on advancing therapeutic approaches in oncology [2]. - Dr. Guy Travis Clifton has been appointed as Chief Medical Officer, enhancing the company's expertise in clinical program advancement and regulatory strategy [2]. R&D Pipeline Progress - The RedTail platform is highlighted as a key focus, utilizing an engineered enveloped virus for systemic delivery of genetic medicines to metastatic cancer sites, representing over a decade of research [3][9]. - Recent preclinical data indicates that RedTail demonstrates potent tumor-selective targeting and improved anti-tumor immune modulation, differentiating it in the oncology market [4]. Strategic Partnerships - The company is actively seeking partnerships with leading biopharmaceutical firms to accelerate the development and commercialization of therapies, which could enhance market reach and shareholder value [4]. Future Milestones - The roadmap for the next 18 months includes completing IND-enabling studies for the lead candidate CLD-401, with an IND filing anticipated by the end of 2026 [5]. - An IND for the SuperNova virotherapy (CLD-201) was opened in April 2025, with Phase I trials expected to start by the end of 2025 [6]. Financial Management - As of Q1 2025, the company reported approximately $10.6 million in cash, with efforts to reduce costs and lower the burn rate while retiring most of its debt [7].